Tenaya Therapeutics, Inc.

NasdaqGS:TNYA Stock Report

Market Cap: US$132.3m

Tenaya Therapeutics Management

Management criteria checks 3/4

Tenaya Therapeutics' CEO is Faraz Ali, appointed in Jun 2018, has a tenure of 6.5 years. total yearly compensation is $2.89M, comprised of 20.5% salary and 79.5% bonuses, including company stock and options. directly owns 0.045% of the company’s shares, worth $59.84K. The average tenure of the management team and the board of directors is 2.9 years and 6.5 years respectively.

Key information

Faraz Ali

Chief executive officer

US$2.9m

Total compensation

CEO salary percentage20.5%
CEO tenure6.5yrs
CEO ownership0.05%
Management average tenure2.9yrs
Board average tenure6.5yrs

Recent management updates

Recent updates

Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation

Sep 18
Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation

We're Keeping An Eye On Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Rate

Jun 04
We're Keeping An Eye On Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Rate

Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation

Dec 20
Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation

Is Tenaya Therapeutics (NASDAQ:TNYA) In A Good Position To Deliver On Growth Plans?

Aug 08
Is Tenaya Therapeutics (NASDAQ:TNYA) In A Good Position To Deliver On Growth Plans?

Tenaya Therapeutics (NASDAQ:TNYA) Will Have To Spend Its Cash Wisely

Mar 07
Tenaya Therapeutics (NASDAQ:TNYA) Will Have To Spend Its Cash Wisely

Can Tenaya Therapeutics (NASDAQ:TNYA) Afford To Invest In Growth?

Dec 06
Can Tenaya Therapeutics (NASDAQ:TNYA) Afford To Invest In Growth?

Tenaya Therapeutics gets U.S. FDA clearance for starting human trial of heart failure treatment

Sep 06

Tenaya Therapeutics GAAP EPS of -$0.69 beats by $0.07

Aug 10

Is Tenaya Therapeutics (NASDAQ:TNYA) In A Good Position To Deliver On Growth Plans?

Aug 08
Is Tenaya Therapeutics (NASDAQ:TNYA) In A Good Position To Deliver On Growth Plans?

We're Hopeful That Tenaya Therapeutics (NASDAQ:TNYA) Will Use Its Cash Wisely

Mar 03
We're Hopeful That Tenaya Therapeutics (NASDAQ:TNYA) Will Use Its Cash Wisely

Companies Like Tenaya Therapeutics (NASDAQ:TNYA) Are In A Position To Invest In Growth

Nov 01
Companies Like Tenaya Therapeutics (NASDAQ:TNYA) Are In A Position To Invest In Growth

Tenaya Therapeutics: Treating Heart Disease Through 3 Product Platforms

Aug 06

CEO Compensation Analysis

How has Faraz Ali's remuneration changed compared to Tenaya Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$117m

Jun 30 2024n/an/a

-US$121m

Mar 31 2024n/an/a

-US$125m

Dec 31 2023US$3mUS$594k

-US$124m

Sep 30 2023n/an/a

-US$128m

Jun 30 2023n/an/a

-US$129m

Mar 31 2023n/an/a

-US$124m

Dec 31 2022US$6mUS$571k

-US$124m

Sep 30 2022n/an/a

-US$116m

Jun 30 2022n/an/a

-US$104m

Mar 31 2022n/an/a

-US$91m

Dec 31 2021US$5mUS$494k

-US$73m

Sep 30 2021n/an/a

-US$57m

Jun 30 2021n/an/a

-US$49m

Mar 31 2021n/an/a

-US$42m

Dec 31 2020US$750kUS$425k

-US$38m

Compensation vs Market: Faraz's total compensation ($USD2.89M) is above average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: Faraz's compensation has been consistent with company performance over the past year.

CEO

Faraz Ali (51 yo)

6.5yrs

Tenure

US$2,890,062

Compensation

Mr. Faraz Ali, M.B.A., serves as Chief Executive Officer since June 2018 & Director since September 2018 at Tenaya Therapeutics, Inc. and served as its Secretary since June 2018. Mr. Ali served as Chief Bu...

Leadership Team

NamePositionTenureCompensationOwnership
Faraz Ali
CEO & Director6.5yrsUS$2.89m0.045%
$ 59.8k
Deepak Srivastava
Scientific Founderno dataUS$280.39k0.71%
$ 942.0k
Whittemore Tingley
Chief Medical Officer6yrsUS$1.38m0.055%
$ 72.4k
Eric Olson
Scientific Founder & Member of Scientific Advisory Boardno datano datano data
Bruce Conklin
Scientific Founderno datano datano data
Saptarsi Haldar
Scientific Founderno datano datano data
Sheng Ding
Scientific Founderno datano datano data
Benoit Bruneau
Scientific Founderno datano datano data
Chihiro Saito
Senior Accounting & Financial Operations and Interim Principal Accounting Officerless than a yearno data0.020%
$ 26.4k
Kee-Hong Kim
Chief Technology Officer2.8yrsno datano data
Michelle Corral
Vice President of Investor Relationship & Corporate Communicationsno datano datano data
Jennifer Drimmer
General Counsel & Corporate Secretary2.9yrsno datano data

2.9yrs

Average Tenure

58yo

Average Age

Experienced Management: TNYA's management team is considered experienced (2.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Faraz Ali
CEO & Director6.5yrsUS$2.89m0.045%
$ 59.8k
Deepak Srivastava
Scientific Founder8.2yrsUS$280.39k0.71%
$ 942.0k
Eric Olson
Scientific Founder & Member of Scientific Advisory Boardno datano datano data
David Goeddel
Independent Chairman of the Board8.3yrsUS$228.89kno data
Mark Kay
Member of Scientific Advisory Boardno datano datano data
Jeffrey Walsh
Independent Director4.8yrsUS$214.89k0%
$ 0
Douglas Mann
Member of Scientific Advisory Boardno datano datano data
Timothy Hoey
Member of Scientific Advisory Boardless than a yearUS$2.56m0.25%
$ 326.2k
R. Williams
Independent Director8.2yrsUS$207.39k0.038%
$ 50.1k
Jonathan Weissman
Member of Scientific Advisory Boardno datano datano data
Elizabeth McNally
Member of Scientific Advisory Boardno datano datano data
Catherine Stehman-Breen
Independent Director4.5yrsUS$202.39k0.010%
$ 13.6k

6.5yrs

Average Tenure

63yo

Average Age

Experienced Board: TNYA's board of directors are considered experienced (6.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 07:05
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Tenaya Therapeutics, Inc. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Whitney IjemCanaccord Genuity
Yevgeniya LivshitsChardan Capital Markets, LLC
Emanuela BranchettiH.C. Wainwright & Co.